Our Approach
A differentiated approach to driving long-term value
Our strategy is designed to compound long-term value by integrating royalty growth, strategic acquisitions, and internal innovation, all supported by a strengthened financial foundation and thoughtful capital allocation.
We operate with a disciplined approach to investing to create a diversified portfolio of healthcare assets that produce durable and predictable revenue streams for our shareholders.
Royalty Growth
As partnered therapies like Ziihera® and pasritamig progress through late-stage development and commercialization, we anticipate durable and predictable cash flows that enable us deploy capital with a focus on best possible risk-adjusted return to shareholders.
Healthcare Asset Acquisitions
A key part of our investment strategy is to acquire programs and/or companies with valuable assets or partnerships. Through adding our scientific and development value and efficiency improvements, we can realize the underlying value of these assets through new royalty streams through partnerships.
Selection criteria:
- Strong clinical differentiation
- Addresses unmet medical need
- Solid patent protection
- Time to market
In-house R&D Engine
Zymeworks’ robust R&D engine is advancing a pipeline of innovative multifunctional therapeutics and utilizing our technology platforms, which represent potential opportunities to form new partnerships and collaborations. Future partnerships and collaborations play an important role in funding ongoing R&D investments, reducing reliance on our internal capital and preserving the long-term value of its existing scientific programs. This continued discipline in capital allocation to R&D investments and financial contributions from existing and new potential partnerships, coupled with risk-sharing for late-stage development, will help reduce the need to use future milestone and royalty payments from our portfolio to fund planned R&D operations.
Partner with us
Integrating partnerships and collaborations is core to our business strategy and allows us to accelerate our efforts to bring novel therapeutics to the broadest group of patients.
